Business
Nuvectis Pharma to Host KOL Event to Discuss Its Two Precision Medicine Clinical-Stage Drug Candidates, NXP800 and NXP900
Virtual Event to be held on Thursday, September 14, 2023 at 10:00 a.m. ET Fort Lee, NJ, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ:
About this update from Nuvectis Pharma, Inc.
[{"type":"text","content":"Virtual Event to be held on Thursday, September 14, 2023 at 10:00 a.m. ET\nFort Lee, NJ, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) (\"Nuvectis\" or the \"Company\"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced it will host a virtual KOL event to discuss its two clinical-stage drug candidates, NXP800 and NXP900, on Thursday, September 14, 2023 at 10:00am ET. To register for the event, please click here. The event will feature Bradley J. Monk, MD, FACS, FACOG (University of Arizona College of Medicine) and Ramez N. Eskander, MD (University of California San Diego) who will discuss the clinical development opportunity for NXP800 in ovarian cancer, and specifically in patients with platinum resistant, ARID1a-mutated ovarian carcinoma, a patient population that is currently being enrolled into an ongoing Phase 1b clinical trial in which the safety and preliminary efficacy of NXP800 is being investigated, and Gordon Mills, MD, PhD (Knight Cancer Institute, Oregon Health & Science University) who will discuss the clinical development opportunities for NXP900 as the Phase 1a dose escalation study is about to commence. A live question and answer session will follow the formal presentations. About Bradley J. Monk, MD, FACS, FACOGDr. Monk is a professor on the Clinical Scholar Track at the University of Arizona College of Medicine – Phoenix and works at the Virginia G. Piper Cancer Center at HonorHealth, Scottsdale, AZ, where he is the Director and Principal Investigator of Community Research Development. Dr. Monk continues to practice medicine in metropolitan Phoenix. After graduating top of his class from the University of Arizona College of Medicine – Tucson, AZ, Dr. Monk completed a residency in obstetrics and gynecology at the University of California, LA. He was later appointed Director of Gynecologic Oncology at Texas Tech University Health Services Center. Following this, Dr. Monk furthered his experience in gynecological oncology in multiple roles including Director and Professor in the Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Creighton University School of Medicine at St. Joseph’s Hospital and Medical Center in Phoenix...